Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sana Biotechnology, Inc.SANA · Entity 4870 | EVP & General Counsel | March 06, 2025 | March 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sana Biotechnology, Inc.
Report date March 06, 2025 · Filed March 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 115,823 |
Reported balance
After 2025-03-07 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-07 · Exercise / conversion · Acquired 11,041 · Balance 115,823 F1: Includes 3,001 shares acquired on May 15, 2023 and 3,000 shares acquired on each of November 15, 2023, May 15, 2024 and November 15, 2024, in each case, pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 112,990 |
Reported balance
After 2025-03-10 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2025-03-10 · Tax withholding · Disposed 2,833 · Balance 112,990 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 53,333 |
Reported balance
After 2025-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-06 · Grant · Acquired 53,333 · Balance 53,333 F2: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F3: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 33,126 |
Reported balance
After 2025-03-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-03-07 · Exercise / conversion · Disposed 11,041 · Balance 33,126 F2: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F5: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2035-03-05 | Direct | 240,000 |
Reported balance
After 2025-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-03-06 · Grant · Acquired 240,000 · Balance 240,000 F4: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 3,001 shares acquired on May 15, 2023 and 3,000 shares acquired on each of November 15, 2023, May 15, 2024 and November 15, 2024, in each case, pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan.
F2: Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
F3: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F4: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
F5: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Juno Therapeutics, Inc.
Report date March 05, 2018 · Filed March 07, 2018
Section 16 reporting ended · disclosed 2018-03-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2018-03-05 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2018-03-05 · Other · Disposed 5,558 · Balance 79,825 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (4) through (7) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. F3: Includes 121 shares acquired under the Company's employee stock purchase plan on February 23, 2018. Row 2 · 2018-03-05 · Disposition to issuer · Disposed 18,293 · Balance 61,532 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F5: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 3 · 2018-03-05 · Disposition to issuer · Disposed 25,639 · Balance 35,893 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F5: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Row 4 · 2018-03-05 · Disposition to issuer · Disposed 35,893 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6: Represents performance-based restricted stock awards ("PSAs"). F7: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017. |
| Common StockSEC Table I · non-derivative | IndirectBy Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA | 0 |
Reported balance
After 2018-03-05 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2018-03-05 · Other · Disposed 26,869 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F8: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2024-09-08 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-05 · Disposition to issuer · Disposed 125,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.72 · Expires 2024-11-13 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-03-05 · Disposition to issuer · Disposed 37,500 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $48.06 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-03-05 · Disposition to issuer · Disposed 50,500 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.50 · Expires 2026-02-01 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2018-03-05 · Disposition to issuer · Disposed 75,000 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.76 · Expires 2027-02-06 | Direct | 0 |
Reported balance
After 2018-03-05 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2018-03-05 · Disposition to issuer · Disposed 113,636 · Balance 0 F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent.
F2: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (4) through (7) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
F3: Includes 121 shares acquired under the Company's employee stock purchase plan on February 23, 2018.
F4: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs").
F5: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement).
F6: Represents performance-based restricted stock awards ("PSAs").
F7: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017.
F8: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes.
F9: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 10, 2025 Filed Mar 10, 2025 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Tax withholdingCommon Stock | 2,833 | $2.56 | $7,252.48 |
DisclosureSEC source: 0001562180-25-002273 · primarydocument.xml · nonDerivative · entry 2 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,990 Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionRestricted Stock Units · Derivative | 11,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002273 · primarydocument.xml · derivative · entry 5 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,126 Underlying: Common Stock · 11,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F5 · derivative.exercise_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. F5 · derivative.expiration_date: The award vested as to 25% of the restricted stock units on March 7, 2025 and the remaining restricted stock units will vest in three equal installments on each of March 7, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date. Read SEC document |
| March 07, 2025 Filed Mar 10, 2025 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 11,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002273 · primarydocument.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 3,001 shares acquired on May 15, 2023 and 3,000 shares acquired on each of November 15, 2023, May 15, 2024 and November 15, 2024, in each case, pursuant to Sana Biotechnology, Inc.'s ("Sana") 2021 Employee Stock Purchase Plan. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 240,000 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001562180-25-002273 · primarydocument.xml · derivative · entry 4 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2035-03-05 F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 6, 2026 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:12 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 53,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002273 · primarydocument.xml · derivative · entry 3 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,333 Underlying: Common Stock · 53,333 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F3 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 6, 2026, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 16:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 198,750 | $0.00 Strike: $9.58 | $0.00 |
DisclosureSEC source: 0001562180-24-002474 · primarydocument.xml · derivative · entry 2 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 198,750 Underlying: Common Stock · 198,750 shares Expires 2034-03-06 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 7, 2025 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 07, 2024 Filed Mar 8, 2024 16:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantRestricted Stock Units · Derivative | 44,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002474 · primarydocument.xml · derivative · entry 1 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,167 Underlying: Common Stock · 44,167 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. ("Sana") common stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. F2 · derivative.expiration_date: The restricted stock units vest in four equal installments on each of March 7, 2025, 2026, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 16:35 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 140,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001562180-23-002396 · primarydocument.xml · derivative · entry 1 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-03-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 2, 2024 and in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2022 Filed Sep 16, 2022 18:52 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Option (Right to Buy) · Derivative | 800,000 | $0.00 Strike: $7.13 | $0.00 |
DisclosureSEC source: 0001562180-22-006711 · primarydocument.xml · derivative · entry 1 Cassidy Bernard J · CIK 0001398322 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires 2032-09-14 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on September 15, 2023 and in 36 equal monthly installments thereafter. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 113,636 | Not disclosed Strike: $20.76 | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · derivative · entry 10 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 113,636 shares Expires 2027-02-06 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $24.50 | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · derivative · entry 9 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2026-02-01 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 50,500 | Not disclosed Strike: $48.06 | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · derivative · entry 8 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,500 shares Expires 2025-03-02 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 37,500 | Not disclosed Strike: $8.72 | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · derivative · entry 7 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires 2024-11-13 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $6.36 | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · derivative · entry 6 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2024-09-08 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F9 · price: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). F9 · derivative.exercise_date: Pursuant to the Merger Agreement, the vested portion of such Options (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested Option and (ii) $87.00 less the applicable exercise price, and the unvested portion (if any) of such Options were assumed by Parent and will be subject to the same terms and conditions as applied to each such Option award immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent option, and the exercise price of such Parent option, will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | OtherCommon Stock | 26,869 | $87.00 | $2,337,603.00 |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · nonDerivative · entry 5 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Indirect · By Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA Disclosed balance after: 0 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F8 · shares: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by Morgan Stanley Smith Barney LLC as Custodian for Bernard Cassidy IRA was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerCommon Stock | 35,893 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · nonDerivative · entry 4 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F6 · shares: Represents performance-based restricted stock awards ("PSAs"). F7 · price: Pursuant to the Merger Agreement, all PSAs will vest as to 50% of the total number of PSAs subject to such awards, and such vested portion will be cancelled and converted into a right to receive an amount in cash equal to the product of (i) such 50% vested portion of the award and (ii) the $87.00. The remaining 50% of the PSAs will be assumed by Parent, provided that the number of shares subject to such PSAs will be adjusted based on the Exchange Ratio (as defined in the Merger Agreement) and the vesting will be adjusted such that (i) 60% of such remaining PSAs will vest on the one-year anniversary of the closing of the Merger and (ii) 40% of such remaining PSAs will vest on the earlier of (A) the second anniversary of the closing of the Merger and (B) the first approval by the U.S. Food and Drug Administration of JCAR017. Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerCommon Stock | 25,639 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · nonDerivative · entry 3 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,893 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · shares: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F5 · price: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Disposition to issuerCommon Stock | 18,293 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · nonDerivative · entry 2 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,532 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F4 · shares: Represents shares of common stock of the Company underlying time-based restricted stock units ("RSUs"). F5 · price: Pursuant to the Merger Agreement, the vested portion of such RSUs (including the portion that received acceleration of vesting under the Merger Agreement) was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the number of shares of common stock subject to such vested awards and (ii) $87.00 and the unvested portion of such RSUs was assumed by Parent and will be subject to the same terms and conditions as applied to each such RSUs immediately prior to the Offer Acceptance Time (as defined in the Merger Agreement), provided that the number of shares subject to such assumed Parent time-based restricted stock unit award was adjusted based on the Exchange Ratio (as defined in the Merger Agreement). Read SEC document |
| March 05, 2018 Filed Mar 7, 2018 18:16 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | OtherCommon Stock | 5,558 | $87.00 | $483,546.00 |
DisclosureSEC source: 0001209191-18-017802 · doc4.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,825 F1 · date: On January 21, 2018, Juno Therapeutics, Inc. (the "Company"), entered into an Agreement and Plan of Merger (the "Merger Agreement") with Celgene Corporation ("Parent"), and Blue Magpie Corporation, a wholly owned subsidiary of Parent ("Purchaser"). On March 5, 2018, Purchaser irrevocably accepted for payment and promptly paid for, all shares of common stock validly tendered and not validly withdrawn pursuant to the Offer (as defined in the Merger Agreement). On March 6, 2018, Purchaser merged with and into the Company pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Company being the surviving corporation (the "Merger") and becoming a wholly-owned subsidiary of Parent. F2 · shares: Pursuant to the terms of the Merger Agreement and the Offer, each share of common stock of the Company held by the Reporting Person, other than as described in notes (4) through (7) below, was validly tendered for $87.00 per share in cash, without interest and subject to withholding of taxes. F3 · shares: Includes 121 shares acquired under the Company's employee stock purchase plan on February 23, 2018. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 19:31 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GiftCommon Stock | 26,634 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009015 · doc4.xml · nonDerivative · entry 2 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,262 F2 · price: Represents a bona fide gift of common stock; thus, there is no price associated with this transaction. Read SEC document |
| February 07, 2018 Filed Feb 9, 2018 19:31 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | Tax withholdingCommon Stock | 1,528 | $85.49 | $130,628.72 |
DisclosureSEC source: 0001209191-18-009015 · doc4.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,896 F1 · kind: Shares withheld by the issuer to satisfy tax withholding obligations on the vesting of restricted stock units. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 19:29 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 25,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-007210 · doc4.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,424 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of January 31, 2018. F2 · balance_after: Includes 431 shares acquired under the issuer's employee stock purchase plan on May 15, 2017 and 437 shares acquired under the issuer's employee stock purchase plan on November 15, 2017. Read SEC document |
| October 20, 2017 Filed Oct 20, 2017 20:26 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 35,893 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-057694 · doc4.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,917 F1 · shares: Represents restricted stock awards ("RSAs") granted pursuant to the 2014 Equity Incentive Plan. The RSAs will become eligible to vest based on the achievement of certain performance goals as follows, subject to the reporting person remaining a service provider to the Issuer through the applicable vesting date: Up to 21,535 shares will become eligible to vest based on the first approval by the U.S. Food & Drug Administration (the "FDA") of JCAR017 in any indication within certain designated timeframes (the "JCAR017 Milestone"). 50% of the shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest immediately upon such achievement. The remaining 50% of shares that become eligible to vest upon the achievement of the JCAR017 Milestone will vest on the one year anniversary of the date of such achievement. Up to 14,358 shares will vest based upon the first approval by the FDA of JCARH125 in any indication within certain designated timeframes. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 19:33 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 1,505 | $46.58 | $70,102.45 |
DisclosureSEC source: 0001209191-17-052873 · doc4.xml · nonDerivative · entry 3 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,024 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017. F4 · price: This transaction was executed in multiple trades at prices ranging from $46.38 to $46.93. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 19:33 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 3,441 | $45.90 | $157,942.59 |
DisclosureSEC source: 0001209191-17-052873 · doc4.xml · nonDerivative · entry 2 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,529 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017. F3 · price: This transaction was executed in multiple trades at prices ranging from $45.34 to $46.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 14, 2017 Filed Sep 14, 2017 19:33 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | SaleCommon Stock | 23,054 | $44.67 | $1,029,720.74 |
DisclosureSEC source: 0001209191-17-052873 · doc4.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,970 F1 · shares: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 23, 2017. F2 · price: This transaction was executed in multiple trades at prices ranging from $44.27 to $45.25. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:34 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantStock Option (Right to Buy) · Derivative | 113,636 | $0.00 Strike: $20.76 | $0.00 |
DisclosureSEC source: 0001209191-17-009294 · doc4.xml · derivative · entry 3 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,636 Underlying: Common Stock · 113,636 shares Expires 2027-02-06 F2 · derivative.exercise_date: 1/48th of the shares subject to the option vests and becomes exercisable on March 7, 2017 and 1/48th of the shares subject to the option vests and becomes exercisable monthly thereafter. Read SEC document |
| February 07, 2017 Filed Feb 9, 2017 19:34 UTC | Juno Therapeutics, Inc. JUNO · Entity 168572 | GrantCommon Stock | 24,390 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009294 · doc4.xml · nonDerivative · entry 1 Cassidy Bernard J · CIK 0001398322 · General Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,024 F1 · shares: Represents restricted stock units ("RSUs") granted pursuant to the 2014 Equity Incentive Plan. 25% of the RSUs vest on each anniversary of February 7, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.